Advantage Alpha Capital Partners LP Invests $285,000 in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Advantage Alpha Capital Partners LP bought a new stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 99,566 shares of the company’s stock, valued at approximately $285,000. Advantage Alpha Capital Partners LP owned approximately 0.10% of Poseida Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Marshall Wace LLP purchased a new stake in Poseida Therapeutics during the 2nd quarter worth about $31,000. Bayesian Capital Management LP acquired a new stake in Poseida Therapeutics during the first quarter worth approximately $33,000. Rothschild Investment LLC purchased a new stake in Poseida Therapeutics in the 2nd quarter worth approximately $35,000. Principal Financial Group Inc. purchased a new position in shares of Poseida Therapeutics during the 2nd quarter worth $35,000. Finally, Intech Investment Management LLC purchased a new position in shares of Poseida Therapeutics during the 3rd quarter worth $46,000. Hedge funds and other institutional investors own 46.87% of the company’s stock.

Analyst Ratings Changes

PSTX has been the topic of several recent analyst reports. Cantor Fitzgerald downgraded Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. HC Wainwright reiterated a “neutral” rating and set a $9.00 price objective (down from $20.00) on shares of Poseida Therapeutics in a report on Tuesday. William Blair restated a “market perform” rating on shares of Poseida Therapeutics in a report on Tuesday. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Poseida Therapeutics in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $9.50.

Poseida Therapeutics Stock Performance

NASDAQ PSTX opened at $9.38 on Wednesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.20 and a quick ratio of 3.20. Poseida Therapeutics, Inc. has a 1-year low of $1.87 and a 1-year high of $9.41. The firm has a market capitalization of $914.17 million, a P/E ratio of -14.89 and a beta of 0.54. The business’s 50-day simple moving average is $2.90 and its 200-day simple moving average is $2.97.

Poseida Therapeutics Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.